1-5. (canceled)
6. A method for treating a mammalian subject with a condition selected from the group consisting of insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis comprising administering to the subject an amount of a biologically active agent, wherein the agent is a compound of the formula:
wherein
n is 1 or 2;
m is 0, 1, 2, 4, or 5;
q is 0 or 1;
t is 0 or 1;
R2 is alkyl having from 1 to 3 carbon atoms;
R3 is hydrogen, halo, alkyl having from 1 to 3 carbon atoms, or alkoxy having from 1 to 3 carbon atoms;
A is phenyl, unsubstituted or substituted by 1 or 2 groups selected from: halo, alkyl having 1 or 2 carbon atoms, perfluoromethyl, alkoxy having 1 or 2 carbon atoms, and perfluoromethoxy; or
cycloalkyl having from 3 to 6 ring carbon atoms wherein the cycloalkyl is unsubstituted or one or two ring carbons are independently mono-substituted by methyl or ethyl; or
a 5 or 6 membered heteroaromatic ring having 1 or 2 ring heteroatoms selected from N, S and O and the heteroaromatic ring is covalently bound to the remainder of the compound of formula I by a ring carbon; and
R1 is hydrogen or alkyl having 1 or 2 carbon atoms;
or when R1 is hydrogen, a pharmaceutically acceptable salt of the compound.
7. The method of claim 6, wherein n is 1; q is 0; t is 0; R3 is hydrogen; and
A is phenyl, unsubstituted or substituted by 1 or 2 groups selected from: halo, alkyl having 1 or 2 carbon atoms, perfluoromethyl, alkoxy having 1 or 2 carbon atoms, and perfluoromethoxy.
8. The method of claim 7, wherein wherein A is 2,6-dimethylphenyl.
9. The method of claim 8, wherein the biologically active agent is selected from the group consisting of:
3-(2,6-Dimethylbenzyloxy)phenylacetic acid;
3-(2,6-Dimethylbenzyloxy)benzoic acid;
Ethyl 3-(2,6-dimethylbenzyloxy)benzoate;
6-3-(2,6-Dimethylbenzyloxy)-phenyl-hexanoic acid;
Ethyl 6-3-(2,6-dimethylbenzyloxy)-phenyl-hexanoate;
5-3-(2,6-Dimethylbenzyloxy)-phenyl-pentanoic acid;
Ethyl 5-3-(2,6-dimethylbenzyloxy)-phenyl-pentanoate;
3-3-(2,6-dimethylbenzyloxy)phenyl-propionic acid; and
Ethyl 3-3-(2,6-dimethylbenzyloxy)phenyl-propanoate.
10. The method of claim 6, wherein the subject is a human.
11. The method of claim 10, wherein the agent is administered orally in an amount from one milligram to four hundred milligrams per day.
12. The method of claim 6, wherein the condition is insulin resistance syndrome or Type II Diabetes.
13. The method of claim 6, wherein the treatment reduces a symptom of diabetes or the chances of developing a symptom of diabetes, wherein the symptom is selected from the group consisting of: atherosclerosis, obesity, hypertension, hyperlipidemia, fatty liver disease, nephropathy, neuropathy, retinopathy, foot ulceration and cataracts, associated with diabetes.
14. A pharmaceutical composition for use in the treatment of a condition selected from the group consisting of insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis, arteriosclerosis and adapted for oral administration, comprising a pharmaceutically acceptable carrier and from one milligram to four hundred milligrams of a biologically active agent, wherein the agent is a compound of the formula:
wherein
n is 1 or 2;
m is 0, 1, 2, 4, or 5;
q is 0 or 1;
t is 0 or 1;
R2 is alkyl having from 1 to 3 carbon atoms;
R3 is hydrogen, halo, alkyl having from 1 to 3 carbon atoms, or alkoxy having from 1 to 3 carbon atoms;
A is phenyl, unsubstituted or substituted by 1 or 2 groups selected from: halo, alkyl having 1 or 2 carbon atoms, perfluoromethyl, alkoxy having 1 or 2 carbon atoms, and perfluoromethoxy; or
cycloalkyl having from 3 to 6 ring carbon atoms wherein the cycloalkyl is unsubstituted or one or two ring carbons are independently mono-substituted by methyl or ethyl; or
a 5 or 6 membered heteroaromatic ring having 1 or 2 ring heteroatoms selected from N, S and O and the heteroaromatic ring is covalently bound to the remainder of the compound of formula I by a ring carbon; and
R1 is hydrogen or alkyl having 1 or 2 carbon atoms;
or when R1 is hydrogen, a pharmaceutically acceptable salt of the compound.
15. The pharmaceutical composition of claim 14, wherein n is 1; q is 0; t is 0; R3 is hydrogen; and
A is phenyl, unsubstituted or substituted by 1 or 2 groups selected from: halo, alkyl having 1 or 2 carbon atoms, perfluoromethyl, alkoxy having 1 or 2 carbon atoms, and perfluoromethoxy.
16. The pharmaceutical composition of claim 15, wherein wherein A is 2,6-dimethylphenyl.
17. The pharmaceutical composition of claim 16, wherein the biologically active agent is selected from the group consisting of:
3-(2,6-Dimethylbenzyloxy)phenylacetic acid;
3-(2,6-Dimethylbenzyloxy)benzoic acid;
Ethyl 3-(2,6-dimethylbenzyloxy)benzoate;
6-3-(2,6-Dimethylbenzyloxy)-phenyl-hexanoic acid;
Ethyl 6-3-(2,6-dimethylbenzyloxy)-phenyl-hexanoate;
5-3-(2,6-Dimethylbenzyloxy)-phenyl-pentanoic acid;
Ethyl 5-3-(2,6-dimethylbenzyloxy)-phenyl-pentanoate;
3-3-(2,6-dimethylbenzyloxy)phenyl-propionic acid; and
Ethyl 3-3-(2,6-dimethylbenzyloxy)phenyl-propanoate.
18. The pharmaceutical composition of claim 14 in oral dosage form.
19. A biologically active agent, wherein the agent is a compound of the formula:
wherein
n is 1 or 2;
m is 0, 1, 2, 4, or 5;
q is 0 or 1;
t is 0 or 1;
R2 is alkyl having from 1 to 3 carbon atoms;
R3 is hydrogen, halo, alkyl having from 1 to 3 carbon atoms, or alkoxy having from 1 to 3 carbon atoms;
A is phenyl, unsubstituted or substituted by 1 or 2 groups selected from: halo, alkyl having 1 or 2 carbon atoms, perfluoromethyl, alkoxy having 1 or 2 carbon atoms, and perfluoromethoxy; or
cycloalkyl having from 3 to 6 ring carbon atoms wherein the cycloalkyl is unsubstituted or one or two ring carbons are independently mono-substituted by methyl or ethyl; or
a 5 or 6 membered heteroaromatic ring having 1 or 2 ring heteroatoms selected from N, S and O and the heteroaromatic ring is covalently bound to the remainder of the compound of formula I by a ring carbon; and
R1 is hydrogen or alkyl having 1 or 2 carbon atoms;
or when R1 is hydrogen, a pharmaceutically acceptable salt of the compound, wherein the agent is substantially pure.
20. The biologically active agent of claim 19, wherein n is 1; q is 0; t is 0; R3 is hydrogen; and
A is phenyl, unsubstituted or substituted by 1 or 2 groups selected from: halo, alkyl having 1 or 2 carbon atoms, perfluoromethyl, alkoxy having 1 or 2 carbon atoms, and perfluoromethoxy.
21. The biologically active agent of claim 20, wherein A is 2,6-dimethylphenyl.
22. The biologically active agent of claim 21, selected from the group consisting of:
3-(2,6-Dimethylbenzyloxy)phenylacetic acid;
3-(2,6-Dimethylbenzyloxy)benzoic acid;
Ethyl 3-(2,6-dimethylbenzyloxy)benzoate;
6-3-(2,6-Dimethylbenzyloxy)-phenyl-hexanoic acid;
Ethyl 6-3-(2,6-dimethylbenzyloxy)-phenyl-hexanoate;
5-3-(2,6-Dimethylbenzyloxy)-phenyl-pentanoic acid;
Ethyl 5-3-(2,6-dimethylbenzyloxy)-phenyl-pentanoate;
3-3-(2,6-dimethylbenzyloxy)phenyl-propionic acid; and
Ethyl 3-3-(2,6-dimethylbenzyloxy)phenyl-propanoate.
23. (canceled)
24. The method of claim 9, wherein the biologically active agent is 3-(2,6-Dimethylbenzyloxy)-phenylacetic acid.
25. The pharmaceutical composition of claim 17, wherein the biologically active agent is 3-(2,6-Dimethylbenzyloxy)-phenylacetic acid.
26. The biologically active agent of claim 22, being 3-(2,6-Dimethylbenzyloxy)-phenylacetic acid.
27. A biologically active agent, wherein the agent is a compound of the formula:
wherein
n is 1 or 2;
m is 0, 1, 2, 4, or 5;
q is 0 or 1;
t is 0 or 1;
R2 is alkyl having from 1 to 3 carbon atoms;
R3 is hydrogen, halo, alkyl having from 1 to 3 carbon atoms, or alkoxy having from 1 to 3 carbon atoms;
A is phenyl, unsubstituted or substituted by 1 or 2 groups selected from: halo, alkyl having 1 or 2 carbon atoms, perfluoromethyl, alkoxy having 1 or 2 carbon atoms, and perfluoromethoxy; or
cycloalkyl having from 3 to 6 ring carbon atoms wherein the cycloalkyl is unsubstituted or one or two ring carbons are independently mono-substituted by methyl or ethyl; or
a 5 or 6 membered heteroaromatic ring having 1 or 2 ring heteroatoms selected from N, S and O and the heteroaromatic ring is covalently bound to the remainder of the compound of formula I by a ring carbon; and
R1 is hydrogen or alkyl having 1 or 2 carbon atoms;
or when R1 is hydrogen, a pharmaceutically acceptable salt of the compound, wherein the agent is present in a mammal other than a mouse.
28. The biologically active agent of claim 27, wherein n is 1; q is 0; t is 0; R3 is hydrogen; and
A is phenyl, unsubstituted or substituted by 1 or 2 groups selected from: halo, alkyl having 1 or 2 carbon atoms, perfluoromethyl, alkoxy having 1 or 2 carbon atoms, and perfluoromethoxy.
29. The biologically active agent of claim 28, wherein A is 2,6-dimethylphenyl.
30. The biologically active agent of claim 29, selected from the group consisting of:
3-(2,6-Dimethylbenzyloxy)phenylacetic acid;
3-(2,6-Dimethylbenzyloxy)benzoic acid;
Ethyl 3-(2,6-dimethylbenzyloxy)benzoate;
6-3-(2,6-Dimethylbenzyloxy)-phenyl-hexanoic acid;
Ethyl 6-3-(2,6-dimethylbenzyloxy)-phenyl-hexanoate;
5-3-(2,6-Dimethylbenzyloxy)-phenyl-pentanoic acid;
Ethyl 5-3-(2,6-dimethylbenzyloxy)-phenyl-pentanoate;
3-3-(2,6-dimethylbenzyloxy)phenyl-propionic acid; and
Ethyl 3-3-(2,6-dimethylbenzyloxy)phenyl-propanoate.
31. The biologically active agent of claim 30, being 3-(2,6-Dimethylbenzyloxy)-phenylacetic acid.
32. The biologically active agent of claim 31, wherein the mammal is a human.
33. The biologically active agent of claim 27, wherein the mammal is a human.
34. A method for treating a mammalian subject with a condition selected from the group consisting of insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis, wherein the active agent is a compound of the formula:
wherein
n is 1 or 2;
m is 0, 1, 2, 4, or 5;
q is 0 or 1;
t is 0 or 1;
R2 is alkyl having from 1 to 3 carbon atoms;
R3 is hydrogen, halo, alkyl having from 1 to 3 carbon atoms, or alkoxy having from 1 to 3 carbon atoms;
A is phenyl, unsubstituted or substituted by 1 or 2 groups selected from: halo, alkyl having 1 or 2 carbon atoms, perfluoromethyl, alkoxy having 1 or 2 carbon atoms, and perfluoromethoxy; or
cycloalkyl having from 3 to 6 ring carbon atoms wherein the cycloalkyl is unsubstituted or one or two ring carbons are independently mono-substituted by methyl or ethyl; or
a 5 or 6 membered heteroaromatic ring having 1 or 2 ring heteroatoms selected from N, S and O and the heteroaromatic ring is covalently bound to the remainder of the compound of formula I by a ring carbon; and
R1 is hydrogen or alkyl having 1 or 2 carbon atoms;
or when R1 is hydrogen, a pharmaceutically acceptable salt of the compound.
35. The method of claim 34, wherein n is 1; q is 0; t is 0; R3 is hydrogen; and
A is phenyl, unsubstituted or substituted by 1 or 2 groups selected from: halo, alkyl having 1 or 2 carbon atoms, perfluoromethyl, alkoxy having 1 or 2 carbon atoms, and perfluoromethoxy.
36. The method of claim 35, wherein A is 2,6-dimethylphenyl.
37. The method of claim 36, wherein the active agent is selected from the group consisting of:
3-(2,6-Dimethylbenzyloxy)phenylacetic acid;
3-(2,6-Dimethylbenzyloxy)benzoic acid;
Ethyl 3-(2,6-dimethylbenzyloxy)benzoate;
6-3-(2,6-Dimethylbenzyloxy)-phenyl-hexanoic acid;
Ethyl 6-3-(2,6-dimethylbenzyloxy)-phenyl-hexanoate;
5-3-(2,6-Dimethylbenzyloxy)-phenyl-pentanoic acid;
Ethyl 5-3-(2,6-dimethylbenzyloxy)-phenyl-pentanoate;
3-3-(2,6-dimethylbenzyloxy)phenyl-propionic acid; and
Ethyl 3-3-(2,6-dimethylbenzyloxy)phenyl-propanoate.
38. The method of claim 37, wherein the active agent is 3-(2,6-Dimethylbenzyloxy)-phenylacetic acid.
39. The method of claim 34, wherein the subject is a human.
40. The method of claim 34, wherein the condition is insulin resistance syndrome or Type II Diabetes.
41. The method of claim 34, wherein the treatment reduces a symptom of diabetes or the chances of developing a symptom of diabetes, wherein the symptom is selected from the group consisting of: atherosclerosis, obesity, hypertension, hyperlipidemia, fatty liver disease, nephropathy, neuropathy, retinopathy, foot ulceration and cataracts, associated with diabetes.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
What is claimed is:
1. In a wireless transmission apparatus for constructing a wireless network by using a plurality of transmission apparatus to transmit information among it and a plurality of other communication stations, said wireless transmission apparatus being characterized by:
interface means for detecting connection bus information of a bus connected to a certain wireless transmission apparatus;
wireless information transmitting means for transmitting corresponding connection bus information to said wireless network;
wireless information receiving means for receiving connection bus information transmitted from other wireless transmission apparatus located within said wireless network; and
internal storage means for storing therein these connection bus information.
2. In a wireless transmission apparatus according to claim 1, said wireless transmission apparatus wherein said wireless information transmitting means transmits said connection bus information to said wireless network when said interface means detects the change of connection bus information.
3. In a wireless transmission apparatus for constructing a wireless network by using a plurality of transmission apparatus to transmit information among it and a plurality of other communication stations, said wireless transmission apparatus being characterized by internal storage means for storing therein connection bus information within said wireless network; and
judging means for judging based on connection bus information of said wireless network whether or not information should be transmitted by radio when it receives wireless transmission information from a connection bus connected to a corresponding wireless transmission apparatus.
4. In a wireless transmission apparatus for constructing a wireless network by using a plurality of transmission apparatus to transmit information among it and a plurality of other communication stations, said wireless transmission apparatus being characterized by:
internal storage means for storing therein connection bus information within said wireless network; and
recognizing means for recognizing a wireless transmission apparatus to which information is transmitted by radio based on connection bus information in each of said other communication stations when it receives wireless transmission information from a connection bus connected to a corresponding wireless transmission apparatus.
5. In a network management method in which a wireless network is comprised of a plurality of transmission apparatus to transmit information, said network management method being wherein network connection bus information connected to a corresponding wireless network is managed by all communication stations comprising said network.
6. In a network management method in which a wireless network is comprised of a plurality of transmission apparatus to transmit information, said network management method being wherein connection bus information of every communication station connected to a corresponding wireless network is managed by all communication stations comprising said network.
7. In a network management method in which a wireless network is comprised of a plurality of transmission apparatus to transmit information, said network management method being wherein, when connection bus information connected to its own communication station connected to a corresponding wireless network is changed, information indicative of said change of connection bus information is transmitted to the whole of said wireless network.
8. In a wireless transmission method in which a wireless network is comprised of a plurality of transmission apparatus to transmit information, said wireless transmission method being wherein, when a destination communication station to which information is transmitted by radio is designated, it is determined based on bus information of wireless transmission information in a corresponding wireless network and network connection bus information connected to a corresponding wireless network whether or not information should be transmitted by radio.
9. In a wireless transmission method in which a wireless network is comprised of a plurality of transmission apparatus to transmit information, said wireless transmission method being wherein, when a destination communication station to which information is transmitted by radio is designated, said destination communication station is designated with reference to bus information of corresponding wireless transmission information and connection bus information connected to every communication station connected to a corresponding wireless network.